- Home
- SAGE vs ACCO Comparison
SAGE vs ACCO Comparison
Compare SAGE & ACCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- ACCO
- Stock Information
- Founded
- SAGE 2010
- ACCO 1893
- Country
- SAGE United States
- ACCO United States
- Employees
- SAGE N/A
- ACCO N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- ACCO Publishing
- Sector
- SAGE Health Care
- ACCO Consumer Discretionary
- Exchange
- SAGE Nasdaq
- ACCO Nasdaq
- Market Cap
- SAGE 571.7M
- ACCO 311.7M
- IPO Year
- SAGE 2014
- ACCO N/A
- Fundamental
- Price
- SAGE $9.20
- ACCO $3.99
- Analyst Decision
- SAGE Hold
- ACCO Buy
- Analyst Count
- SAGE 18
- ACCO 1
- Target Price
- SAGE $10.06
- ACCO $6.00
- AVG Volume (30 Days)
- SAGE 3.0M
- ACCO 850.6K
- Earning Date
- SAGE 07-30-2025
- ACCO 07-31-2025
- Dividend Yield
- SAGE N/A
- ACCO 7.52%
- EPS Growth
- SAGE N/A
- ACCO N/A
- EPS
- SAGE N/A
- ACCO N/A
- Revenue
- SAGE $47,404,000.00
- ACCO $1,624,700,000.00
- Revenue This Year
- SAGE $102.21
- ACCO N/A
- Revenue Next Year
- SAGE $43.01
- ACCO $0.58
- P/E Ratio
- SAGE N/A
- ACCO N/A
- Revenue Growth
- SAGE N/A
- ACCO N/A
- 52 Week Low
- SAGE $4.62
- ACCO $3.32
- 52 Week High
- SAGE $13.47
- ACCO $6.44
- Technical
- Relative Strength Index (RSI)
- SAGE 73.11
- ACCO 66.15
- Support Level
- SAGE $9.04
- ACCO $3.46
- Resistance Level
- SAGE $9.30
- ACCO $4.00
- Average True Range (ATR)
- SAGE 0.15
- ACCO 0.12
- MACD
- SAGE 0.03
- ACCO 0.06
- Stochastic Oscillator
- SAGE 95.50
- ACCO 91.18
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About ACCO Acco Brands Corporation
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.